Search

Search Constraints

You searched for: Author/Creator Garren, Hideki

Search Results

1. 061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Issue 6 (24th May 2018)

2. Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease?. Issue 1 (January 2019)

3. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Issue 4 (16th October 2018)

4. Evaluation of no evidence of progression or active disease (nepad) in patients with primary progressive multiple sclerosis in the oratorio trial. Issue 5 (8th May 2017)

5. Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a. Issue 4 (October 2019)

6. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Issue 1 (March 2018)

7. PO127 Composite confirmed disability progression in oratorio. (1st December 2017)

8. Preliminary results of the opera i and opera ii open-label extension study. Issue 5 (8th May 2017)

9. Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis. Issue 7 (15th January 2019)

10. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Issue 5 (May 2020)